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Purpose: To investigate the relationships among antioxidant activities, oxidative stress, and vascular endothelial growth
factor (VEGF) in the vitreous body and serum from proliferative diabetic retinopathy (PDR) patients.
Methods: In 21 patients with PDR and 21 controls with macular hole (MH), the VEGF and lipid peroxide (Nε-hexanoyl-
lysine [HEL]) levels in the vitreous and serum were measured by enzyme-linked immunosorbent assay, while antioxidant
capacity (potential antioxidant [PAO]) was measured by chemical reduction of Cu2+.
Results: Both the PAO and HEL levels in the vitreous and serum were significantly higher in PDR patients than in those
with MH (both p<0.01). The VEGF concentrations in the vitreous were higher in PDR patients than in those with MH
(p<0.01); however, the VEGF concentrations in the serum were not different between the two groups (p=0.95). Positive
correlations were found between the PAO and VEGF concentrations and between the HEL and VEGF concentrations in
the vitreous of both the PDR and the MH patients.
Conclusions: Our study revealed that the PAO, HEL, and VEGF concentrations in the vitreous were increased in PDR
versus MH patients and that there were positive correlations among these factors. This is consistent with VEGF and lipid
peroxide levels in the vitreous playing some role in the pathogenesis of PDR.
Proliferative  diabetic  retinopathy  (PDR),  one  of  the
complications  of  diabetes,  is  characterized  by  extensive
neovascularization and vessel intrusion into the vitreous body,
resulting in subsequent bleeding surrounding new vessels and
leading to severe visual impairment. This process depends on
the local production of angiogenic factors, such as vascular
endothelial growth factor (VEGF), which potently activates
angiogenesis,  enhances  collateral  vessel  formation,  and
increases permeability of the microvasculature [1]. VEGF
expression,  which  is  induced  by  high  glucose  levels  and
hypoxia, plays important roles in both normal and abnormal
angiogenesis [2,3]. Its levels in the vitreous and aqueous body
of  the  eye  have  been  found  to  be  markedly  increased  in
patients with PDR [4,5]. Moreover, several clinical studies
have shown that increased concentrations of VEGF within the
eye have a strong correlation to the development of PDR [6].
The hyperglycemia-induced endothelial dysfunction that
occurs in diabetes is not fully understood, but oxidative stress
has  been  reported  to  play  a  key  role  in  the  initial  insult.
Multiple biochemical pathways that are known to increase the
production of reactive oxygen species (ROS) have been linked
to  hyperglycemia/diabetes-induced  vascular  injury.  These
pathways include glucose auto-oxidation, the polyol pathway,
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and the formation of advanced glycation endproducts [7,8].
The tissues exposed to oxidative stress in diabetes include
renal and ocular tissues, which tend to suffer damage and
cause some of the complications of diabetes [9,10].
Oxygen free radicals can generate lipid peroxides, which
are the products of oxidative fatty acid [11]. Nε-hexanoyl-
lysine (HEL), an early stage of lipid peroxide, is formed from
a lipid hydroperoxide and a lysine residue. HEL is considered
to  be  one  of  the  stable  oxidative  stress  markers  for  lipid
peroxide and protein modification [12]. A previous report
indicated that HEL production is promoted by oxidatively
modified  low-density  lipoprotein  in  rabbit  atherosclerotic
lesions [13]. Moreover, the plasma concentrations of HEL are
increased  in  patients  with  azoospermia  and  oligospermia
[14].
Oxidative stress is caused by the imbalance between ROS
generation  and  antioxidant  capacity.  Therefore,  for  the
accurate  assessment  of  oxidative  stress,  it  is  important  to
measure both components. The use of potential antioxidant
(PAO) is one of the approaches for evaluating antioxidant
capacity;  in  this  method  Cu2+  is  reduced  by  various
antioxidants to Cu+, which is measured by colorimetry. PAO
enables the evaluation of not only hydrophilic antioxidants,
such  as  vitamin  C  and  glutathione,  but  also  hydrophobic
antioxidants, such as vitamin E. This method also provides a
quantitative  measurement  of  the  antioxidant  capability  of
various biologic fluids, such as plasma and serum [14,15].
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130Therefore, PAO is a useful tool for clinical study to determine
total antioxidant properties.
ROS is an angiogenesis inducer [16], and oxidative stress
is believed to play a pivotal role in the development of diabetic
retinopathy. However, relatively little information is available
on antioxidant capacity and oxidative stress in PDR patients.
In the present study, we aimed to clarify antioxidant capacity
and oxidative stress in the vitreous body from PDR patients.
We measured the following parameters in the vitreous and
serum obtained from PDR and macular hole (MH) patients:
(i) the levels of PAO by evaluating Cu2+ reduction by all
antioxidants present, (ii) the concentrations of HEL (a marker
of early stage lipid peroxide), and (iii) the concentrations of
VEGF. We also designed the present study (a) to evaluate the
relationship between antioxidant activity and oxidative stress
in the vitreous body and serum obtained from PDR patients
and (b) to determine whether the concentrations of VEGF
correlate with other parameters.
METHODS
Subjects and sample collection: This study was conducted
according to the tenets of the Declaration of Helsinki and was
performed  after  receiving  approval  from  the  institutional
review committee of Osaka Medical College located in Osaka,
Japan.  Written  informed  consent  was  obtained  from  all
patients after an explanation of the purpose of the study and
the procedures involved.
The diabetic patients with PDR (10 men, 11 women) had
an average age of 54.1 years (standard deviation [SD] ±13.6),
while the average age of the patients with nondiabetic MH (7
men,  14  women)  was  63.1±5.7  years.  Undiluted  vitreous
samples were collected from 42 eyes of 42 individuals (PDR,
21 eyes; MH, 21 eyes) undergoing pars plana vitrectomy for
the  treatment  of  diabetic  retinopathy  and  other  retinal
disorders at Osaka Medical College Hospital. Samples with
repeat vitrectomy were excluded. We excluded the persons
who  had  undergone  repeated  vitrectomy,  and  after  the
judgment,  we  used  in  the  experiments  (vitreous  samples:
PDR, 21 eyes; MH, 21 eyes, serum samples: PDR, 17 patients;
MH,  18  patients).  imultaneously,  serum  samples  were
collected from 35 individuals (PDR, 17 patients; MH, 18
patients). PDR patients with or without macular edema and
traction  membrane  were  included.  MH  patients  without
neovascular disease and vitreous hemorrhage were used as the
controls for nondiabetic ocular disease because MH is caused
by vitreomacular traction and we assumed that the vitreous
body from patients with MH would be the most similar in
constitution to normal eyes. Details of the patients with PDR
and MH are shown in Table 1.
Before intraocular infusion of a balanced salt solution,
the vitreous core was cut and aspirated via the pars plana, with
a vitreous cutter. The samples of vitreous bodies (0.6–0.8 ml)
were spun for 10 min at 15,000× g in a refrigerated centrifuge
at 4 °C to remove particles and then were stored in aliquots in
polypropylene tubes at −80 °C until assay. At the same time
as  vitreous  surgery,  the  samples  of  serum  (2.0  ml)  were
collected in sterile tubes and rapidly frozen at −80 °C.
Measurement of potential antioxidant levels: The evaluation
of antioxidant capacity in vitreous and serum samples was
performed by means of a PAO test (Nikken Seil Co., Ltd,
Shizuoka,  Japan).  This  method  provides  a  quantitative
measurement of the antioxidant capability of a biologic fluid,
such as serum and plasma [14,15]. The antioxidant capability
of our samples was obtained by evaluating Cu+ derived by the
reduction of Cu2+ (Nikken Seil Co., Ltd., Shizuoka, Japan),
which was added at known concentrations either to standard
TABLE 1. DATA FOR PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY OR MACULAR HOLE .
Characteristic Macular hole
 (21 patients)
Proliferative diabetic retinopathy
(21 patients)
Age (years) 63.1±5.7 54.1±13.6
Number of women 14 11
Clinical findings
Vitreous hemorrhage − 21
+Traction membrane − 12
+Cystoid macular edema − 6
MH Stage 2 1 −
MH Stage 3 14 −
MH Stage 4 6 −
The table indicates the baseline characteristics and the complications of proliferative diabetic retinopathy and macular hole
patients. Complications of each patient are shown in “clinical findings.” In proliferative diabetic retinopathy, majority of
complications were vitreous hemorrhage. In macular hole patients, 1 patient was macular hole stage2, 14 patients were macular
hole stage3, and 6 patients were macular hole stage 4. “Age” data are mean±SD.
Molecular Vision 2010; 16:130-136 <http://www.molvis.org/molvis/v16/a16> © 2010 Molecular Vision
131or to experimental samples. Cu+ forms a stable complex with
bathocuproine  (2,9-dimethyl-4,7-diphenyl-1,10-
phenanthroline; Nikken Seil Co.), a colorimetric reagent of
Cu+, and the complex has a typical absorption at 480–490 nm.
The  absorbance  was  measured  using  a  microplate  reader
(Varioskan Flash TOP/BOTTOM; Thermo Fisher Scientific
Inc., Waltham, MA).
Measurement of Nε-hexanoyl-lysine levels: HEL is a lipid
hydroperoxide-modified lysine residue that is considered to
be a useful marker of early lipid peroxidation-derived protein
modification  [17].  HEL  levels  were  determined  with  a
competitive enzyme-linked immunosorbent assay (ELISA)
kit (Nikken Seil Co., Ltd), which is used for quantitative
measurement of hexanoyl lysine adducts. Using the ELISA
method,  minute  concentrations  of  HEL  can  be  detected.
Methods were performed according to the manufacturer’s
recommendations.
Briefly,  microtiter  plates  (Nunc,  Roskilde,  Denmark)
were coated with sample (10 mg protein/ml diluted with PBS).
The  coating  solution  was  discarded,  and  the  wells  were
washed three times with PBS containing 0.05% Tween-20
(TPBS; Bio-Rad, Tokyo, Japan), followed by distilled water.
Each well was incubated with 100 ml of monoclonal antibody
(Nikken Seil Co., Ltd.) against HEL for 2 h at 37 °Cwith
shaking. After being washed with TPBS and distilled water,
the wells were incubated for 1 h at 37 °C with 100 ml of
peroxidase-labeled goat anti-mouse IgG (American Qualex,
La Mirada, CA) diluted 1:5000 in TPBS. After another wash,
100  ml  of  o-phenylenediamine  solution  [5  mg  of  o-
phenylenediamine (ICN Pharmaceuticals, Inc., Mesa, CA)
and 10 ml of 30% H2O2 (Wako Pure Chemical Industries,
Osaka, Japan) in 10 ml of 0.1 M citrate phosphate buffer, pH
5.5 (Polysciences, Inc., Warrington, PA)] was added to each
well.  The  plates  were  incubated  for  15  min  at  room
temperature.  Adding  50  ml  of  2N  sulfuric  acid  (Wako)
terminated the reaction. Absorbance at 492 nm was read using
a  microplate  reader  (VarioskanR  Flash,  Thermo  Electron
Corporation, Vantaa, Finland).
Measurement  of  vascular  endothelial  growth  factor
concentrations: The VEGF concentrations in vitreous body
and serum were measured using a human VEGF ELISA kit
(Pierce  Biotechnology,  Rockford,  IL).  In  brief,  50  ml  of
sample diluent and 50 ml of either the standard control or a
fivefold diluted vitreous body or serum sample were added to
each well of the ELISA plate, incubated for 2 h at room
temperature, and washed three times at room temperature
(Endogen VEGF ELISA Kit). Then, 100 ml of anti-human
VEGF biotinylated antibody reagent (Endogen VEGF ELISA
Kit)  was  added  to  each  well,  incubated  for  1  h  at  room
temperature, and washed three times at room temperature.
Streptavidin-  horseradish  peroxidase  (HRP)  reagent
(Endogen  VEGF  ELISA  Kit)  was  added  to  each  well,
incubated for 30 min at room temperature, and then washed
three times at room temperature. Next, 100 ml TMB substrate
solution (Endogen VEGF ELISA Kit) was added to each well,
and the plate was developed in darkness at room temperature
for 30 min. Finally, 100 ml of stop solution was added, and
concentrations were determined at 450 nm (correction 550
nm) using a microplate reader.” Further information is not
clear, because the details are not described in instruction of
“Endogen VEGF ELISA Kit.
Statistical analysis: Statistical analysis was performed with
the aid of the Statistical Package for the Social Sciences 15.0J
for Windows software (SPSS Japan Inc., Tokyo, Japan). Data
are presented as mean±SD. Statistical comparisons were made
using the Kruskal–Wallis test, followed by the Tukey test. To
examine  correlations,  the  Pearson's  product-moment
correlation  coefficient  was  used.  A  value  of  p<0.05  was
considered to indicate statistical significance.
Figure 1. Potential antioxidant and Nε-
hexanoyl-lysine  levels  in  proliferative
diabetic retinopathy and macular hole
patients. The vitreous and serum levels
of (A) potential antioxidant (PAO) and
(B)  Nε-hexanoyl-lysine  (HEL)  were
significantly  higher  in  proliferative
diabetic  retinopathy  (PDR)  versus
macular hole (MH). *p<0.05, **p<0.01
versus MH (Tukey test).
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Potential antioxidant levels: As shown in Figure 1A, the PAO
levels in the vitreous and serum were significantly higher
(p<0.01)  in  the  PDR  patients  (505.0±145.0  μmol/l  and
1177.9±207.8 μmol/l, respectively) than in the MH patients
(331.7±193.5 μmol/l and 962.5±97.6 μmol/l, respectively).
Repeated within-run and between-run assay variabilities were
always lower than 5%.
Nε-hexanoyl-lysine levels: As shown in Figure 1B, the levels
of HEL in the vitreous and serum were significantly higher
(p<0.05) in PDR patients (4.9±0.8 nmol/l and 4.9±1.6 nmol/
l,  respectively)  than  in  MH  patients  (4.3±0.7  nmol/l  and
3.5±1.4 nmol/l, respectively).
Relationship between potential antioxidant and Nε-hexanoyl-
lysine levels: In the PDR patients, there was a significant
positive correlation between PAO and HEL levels both in the
vitreous body (r=0.65, p<0.01) and the serum (r=0.55, p<0.05;
Figure 2C,D). On the other hand, there was no significant
correlation between PAO and HEL levels either in the vitreous
body (r=0.27, p=0.17) or the serum (r=0.32, p=0.17) obtained
from the MH patients (Figure 2A,B).
Vascular endothelial growth factor concentrations: As shown
in Figure 3, the concentrations of VEGF in the vitreous were
strikingly higher (p<0.01) in the PDR (598.8±604.5 pg/ml)
than in the MH (30.9±21.9 pg/ml) patients. In contrast, the
concentrations of VEGF in the serum were not significantly
Figure 3. Vascular endothelial growth factor concentrations in the
vitreous body and serum from proliferative diabetic retinopathy and
macular hole patients. The VEGF concentrations in the vitreous were
much higher in PDR than in MH patients. In contrast, the VEGF
concentrations in the serum were not significantly different between
PDR and MH patients. **, p<0.01 versus MH (vitreous body; Tukey
test).
Figure  2.  Relationships  between
potential antioxidant and Nε-hexanoyl-
lysine in the vitreous body and serum
from proliferative diabetic retinopathy
and  macular  hole  patients.  In  the
vitreous  body  (A)  and  serum  (B),  no
significant  correlations  were  evident
between PAO and HEL levels in MH
patients.  C:  There  was  a  positive
correlation  between  PAO  and  HEL
levels  in  the  vitreous  body  (r=0.65,
p<0.01)  in  PDR  patients.  D:  The
concentrations of PAO and HEL in the
serum  showed  a  positive  correlation
(r=0.55,  p<0.05)  in  PDR  patients.
Correlations were examined using the
Pearson's  product-moment  correlation
coefficient.
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133different between the two patient groups (PDR, 253.4±229.3
pg/ml; MH, 199.6±111.2 pg/ml; p=0.95).
Relationships between vascular endothelial growth factor and
potential antioxidant levels and between vascular endothelial
growth factor and Nε-hexanoyl-lysine levels: We performed
association-based analysis to examine possible relationships
between VEGF and PAO levels and between VEGF and HEL
levels in the vitreous and the serum samples (Figure 4). In the
vitreous  body,  VEGF  concentrations  were  positively
correlated  with  PAO  (r=0.39,  p<0.05)  and  HEL  (r=0.42,
p<0.05) levels in all patients (Figure 4A,C). However, in the
serum, VEGF concentrations were not significantly correlated
with PAO (r=-0.35, p=0.10) or HEL (r=-0.23, p=0.31) levels
(Figure 4B,D).
DISCUSSION
In the present study, we investigated the concentrations of
PAO, HEL, and VEGF in vitreous and serum samples taken
from  PDR  and  MH  patients.  The  PAO  and  HEL
concentrations  in  both  the  vitreous  and  serum  were
significantly  higher  in  the  PDR  patients  than  in  the  MH
patients. We found a positive correlation between PAO and
HEL levels both in the vitreous and the serum obtained from
the PDR patients. In addition, the VEGF concentrations in the
vitreous were higher in the PDR than in the MH patients, and
there was a positive correlation between VEGF and PAO
levels and between VEGF and HEL levels in the vitreous body
from all patients. This is the first time that the novel lipid
peroxide HEL has been measured in the vitreous body from
PDR patients.
Retinal neovascularization is one pathogenesis of PDR.
Previous reports have indicated that neovascularization is well
correlated with VEGF concentrations in the vitreous but not
in the serum [4,5], which is consistent with the results of our
study. It is unclear why the vitreous VEGF concentrations of
PDR  patients  are  more  than  20  times  higher  than
concentrations in the nondiabetic controls (MH patients), but
it is certain that the upregulation of VEGF in the vitreous is
an important factor in the pathogenesis of PDR [6].
Over the past decade there has been substantial interest
in oxidative stress and its potential roles in diabetogenesis,
development of diabetic complications, atherosclerosis, and
associated cardiovascular disease. Consequences of oxidative
stress lead to damage of DNA, proteins, and lipids, disruption
in  cellular  homeostasis,  and  accumulation  of  damaged
molecules. Previous reports showed that levels of the lipid
peroxidative  products  4-hydroxynonenal  and
malondialdehyde in the vitreous and serum are significantly
higher  in  patients  with  diabetic  retinopathy  than  in
nondiabetic controls [16]. In the present study, an increase in
HEL  concentrations  was  observed  in  the  vitreous  bodies
obtained from PDR patients, suggesting that oxidative stress
Figure  4.  Relationships  between
potential  antioxidant  and  vascular
endothelial growth factor and between
Nε-hexanoyl-lysine  and  vascular
endothelial growth factor in the vitreous
body  and  serum  from  proliferative
diabetic retinopathy and macular hole
patients. A: The vitreous concentrations
of  PAO  and  VEGF  displayed  a
significant correlation (r=0.39, p<0.05).
B: In the serum, there was no significant
correlation  between  PAO  and  VEGF
concentrations. C: The HEL and VEGF
concentrations in the vitreous showed a
significant correlation (r=0.42, p<0.05).
D: In the serum, there was no significant
correlation  between  HEL  and  VEGF
concentrations. Open circles and closed
circles indicate MH and PDR patients,
respectively  (vitreous  body).  Open
triangles and closed triangles indicate
MH  and  PDR  patients,  respectively
(serum).  Correlations  were  examined
using  the  Pearson's  product-moment
correlation coefficient.
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134(such as ROS generation) may lead to cellular damage and to
disease development and pathogenesis in PDR patients.
ROS  generation  also  plays  a  pivotal  role  against
angiogenesis via upregulation of VEGF expression both in
vitro and in vivo [18]. Colavitti et al. reported that ROS is one
of the downstream mediators of the VEGF signaling pathway
[19],  while  Ushio-Fukai  and  colleagues  noted  that  the
angiogenic effects of ROS are attenuated by N-acetylcysteine,
a metabolic precursor of reduced glutathione, in endothelial
cells [20]. Hence, ROS may perform pivotal roles in various
angiogenic events. In the present study, an increase in lipid
peroxide (as represented by HEL) and VEGF levels were
observed in the vitreous bodies obtained from PDR patients,
and there was a significant correlation between HEL and
VEGF concentrations in the vitreous bodies from both groups
of patients. These results indicate that oxidative stress, such
as from increased ROS generation, may play a pivotal role in
the  upregulation  of  VEGF  in  the  vitreous  body  in  PDR
patients.
In  our  study,  the  intravital  antioxidant  capacity  was
increased during a state of enhanced oxidative stress in an
advanced stage of diabetic retinopathy; however, some reports
have indicated that antioxidant capacity is decreased in PDR
patients [21,22]. This discrepancy in antioxidant capacity may
be  a  result  of  focusing  on  different  types  of  antioxidant
enzymes. Although catalase and glutathione are decreased in
PDR patients [21,22], extracellular SOD is upregulated in
PDR patients [23]. These results indicate that the increased
antioxidant capacity in the present study may result from the
summation of increased and decreased antioxidant capacity
of  various  enzymes.  However,  further  investigations  are
needed  to  clarify  the  antioxidant  capacity  of  individual
enzymes in PDR patients.
ROS are products of normal cellular metabolism and are
known  to  act  as  second  messengers.  Under  pathological
conditions,  ROS  generation  in  various  diseases  is
accompanied by activation of redox homeostasis to protect
cells against oxidative stress. In our study the total antioxidant
capacity was increased with accompanying upregulation of
HEL in the vitreous body from PDR patient. Understanding
how  the  redox  regulatory  system  increase  the  antioxidant
capacity  in  the  vitreous  bodies  in  PDR  patients.  Redox
regulation is essential machinery to maintain homeostasis of
redox  state.  Major  factors  to  regulate  redox  state  are
glutathione,  thioredoxin,  and  nuclear  factor  erythroid-2-
related  factor  2  (Nrf2)  pathway  [24].  The  glutathione
antioxidant  system  is  one  of  the  redox  regulations.
Nicotinamide adenine dinucleotide phosphate is required to
maintain the glutathione cycles, but in diabetes mellitus it is
known that activation of the polyol pathway leads to depletion
of  NADPH,  which  results  in  the  antioxidant  capacity  of
glutathione  being  decreased  in  diabetes  patients  [25].  A
second  redox  regulation  is  thioredoxin.  A  previous  study
indicated that thioredoxin levels are significantly higher in
diabetic  patients  than  in  healthy  controls  [26].  A  third
candidate is nuclear factor erythroid-2-related factor 2 (Nrf2).
Nrf2 is a redox-sensitive transcription factor that binds to the
antioxidant response element (ARE) in the promoter region
of phase II detoxifying and antioxidant enzymes, leading to
an upregulation of antioxidant gene expression in vascular
cells. In diabetes patients glutathione-s-transferase, one of the
downstream genes regulated by the Nrf2/ARE pathway, is
upregulated  [25].  Moreover,  hyperglycemia-induced  ROS
production is exacerbated in Nrf2 knockout mice [27,28],
further  implicating  the  Nrf2/ARE  pathway  in  the  defense
against  oxidative  stress  in  diabetic  complications.  These
findings indicate that the thioredoxin and Nrf2/ARE pathways
are candidates for redox regulation to maintain the redox
status  in  the  vitreous  body  from  PDR  patients.  However,
further  examination  is  needed  to  clarify  the  relationship
between PDR and the redox regulation.
In summary, our results reveal that lipid peroxides and
antioxidant activities were increased in the vitreous body and
serum samples obtained from PDR patients and there were
positive  correlations  among  these  factors.  Moreover,
increased VEGF concentrations were significantly correlated
with lipid peroxide concentrations and antioxidant activities
in the vitreous body from PDR patients. These results suggest
that  lipid  peroxides  and  antioxidants  to  involved  in  the
pathogenesis of PDR.
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